Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Rhea-AI Summary
Merck (MRK) and Daiichi Sankyo have initiated the IDeate-Prostate01 phase 3 trial for ifinatamab deruxtecan (I-DXd), a potential first-in-class B7-H3 directed antibody drug conjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will evaluate I-DXd against docetaxel in patients whose disease progressed during or after androgen receptor pathway inhibitor treatment. This marks the third pivotal trial in the I-DXd development program. The decision follows promising results from the IDeate-PanTumor01 phase 1/2 trial presented at ESMO 2022 and 2023. The development addresses a significant medical need, as advanced prostate cancer's five-year survival rate drops to 31%, compared to 90% for localized cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
-
Rhea-AI Summary
Merck announced FDA approval of KEYTRUDA (pembrolizumab) for treating resectable locally advanced head and neck squamous cell carcinoma (HNSCC) with PD-L1 expression. This marks the first perioperative anti-PD-1 treatment regimen for this condition. Based on the Phase 3 KEYNOTE-689 trial, KEYTRUDA showed significant efficacy, reducing the risk of event-free survival events by 30% compared to standard care. The median EFS was 59.7 months for KEYTRUDA versus 29.6 months for standard care. The approval introduces a new treatment paradigm where KEYTRUDA is used before surgery (neoadjuvant), after surgery with radiotherapy/cisplatin (adjuvant), and then as a single agent. The drug demonstrated a manageable safety profile, though immune-mediated adverse reactions can occur. This approval was reviewed under Project Orbis, with applications under review globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
-
News
Rhea-AI Summary
Merck Animal Health (NYSE:MRK) has received a positive opinion from the European Medicines Agency's CVMP for NUMELVI (atinvicitinib) Tablets for Dogs. NUMELVI is set to become the first and only second-generation JAK inhibitor for treating pruritus associated with allergic dermatitis and atopic dermatitis in dogs. The once-daily treatment is at least 10-fold more selective for JAK1 compared to other JAK family members, offering a superior safety profile while maintaining efficacy. Notable features include its use in dogs as young as six months old, effectiveness from the first dose, and no impact on vaccination immune response. The treatment addresses a significant market, as itch affects over 20% of dogs in general veterinary practice. European Commission's marketing authorization decision is expected in Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
Rhea-AI Summary
Merck (NYSE: MRK) has initiated MOBILIZE-1, its first Phase 3 clinical trial for V181, a novel quadrivalent dengue vaccine candidate. The study aims to evaluate the safety, immunogenicity, and efficacy of a single-dose vaccine designed to prevent dengue disease caused by all four dengue virus serotypes, regardless of prior exposure. The trial has begun recruitment in Singapore, marking a significant milestone in addressing this widespread mosquito-borne disease that threatens approximately half of the world's population. V181 could potentially offer a crucial single-dose preventive option for at-risk populations globally. Merck plans to conduct trials in various regions where dengue poses a significant health threat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
-
Rhea-AI Summary
The FDA has approved Merck's (MRK) ENFLONSIA (clesrovimab-cfor), a preventive monoclonal antibody for RSV lower respiratory tract disease in infants. As the first RSV preventive with a uniform 105 mg dose regardless of weight, ENFLONSIA provides protection through 5 months. In the Phase 2b/3 CLEVER trial, ENFLONSIA demonstrated a 60.5% reduction in RSV-associated medically attended lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations compared to placebo. The drug is expected to be available before the 2025-2026 RSV season, with ordering beginning in July 2025. The CDC's Advisory Committee on Immunization Practices will meet to discuss recommendations for ENFLONSIA's use in infants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary
Merck (MRK) announced positive topline results from two Phase 3 trials (CORALreef HeFH and CORALreef AddOn) evaluating enlicitide decanoate, a potential first-in-class oral PCSK9 inhibitor for hyperlipidemia treatment. Both trials met primary and key secondary endpoints, showing significant LDL-C reductions compared to placebo and other oral non-statin therapies. The CORALreef HeFH trial demonstrated efficacy in patients with heterozygous familial hypercholesterolemia, while CORALreef AddOn showed superior results versus ezetimibe and bempedoic acid. The drug showed a favorable safety profile with no meaningful differences in adverse events. The CORALreef program aims to enroll approximately 17,000 patients across several trials, including ongoing CORALreef Lipids and CORALreef Outcomes studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Rhea-AI Summary
Merck (NYSE: MRK) announced that its chairman and CEO Robert M. Davis, along with Dr. Dean Y. Li, executive vice president and president of Merck Research Laboratories, will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference. The event is scheduled for Tuesday, June 10, 2025, at 10:00 a.m. EDT. The presentation will be accessible via live audio webcast to investors, analysts, media representatives, and the general public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary
Merck announced significant results from the Phase 3 ASCENT-04/KEYNOTE-D19 study showing KEYTRUDA plus Trodelvy reduced disease progression or death risk by 35% compared to KEYTRUDA plus chemotherapy in first-line PD-L1+ metastatic triple-negative breast cancer (TNBC). The combination achieved median progression-free survival of 11.2 months versus 7.8 months with KEYTRUDA plus chemotherapy. The study demonstrated higher objective response rate (59.7% vs 53.2%) and longer duration of response (16.5 months vs 9.2 months) for KEYTRUDA plus Trodelvy. The safety profile was consistent with known profiles of both drugs, with no new safety signals identified. This marks the first pivotal Phase 3 trial showing superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate versus standard care in first-line metastatic TNBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
-
Rhea-AI Summary
Merck announced promising Phase 1 KANDLELIT-001 trial results for MK-1084, their investigational KRAS G12C inhibitor, in treating advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) with KRAS G12C mutations. The drug showed encouraging antitumor activity both as monotherapy and in combinations. In CRC, MK-1084 demonstrated confirmed response rates of 38% as monotherapy, 46% when combined with cetuximab, and 38% with cetuximab plus chemotherapy. For NSCLC, response rates were 38% as monotherapy, notably 77% when combined with KEYTRUDA in untreated metastatic cases, and 53% with KEYTRUDA plus chemotherapy. The drug maintained a manageable safety profile across all treatment arms, with treatment-related adverse events ranging from 58% in monotherapy to 97% in combination therapies. Merck plans to advance MK-1084 to Phase 3 trials for both CRC and NSCLC treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
Rhea-AI Summary
Merck announced promising results from the Phase 2/3 waveLINE-003 study of zilovertamab vedotin combined with R-GemOx for treating relapsed/refractory DLBCL. At the 1.75 mg/kg dose, the combination achieved a 56.3% objective response rate, including 8 complete responses and 1 partial response in 16 patients. The study evaluated three dose levels (1.5, 1.75, and 2.0 mg/kg), with 1.75 mg/kg selected as the recommended Phase 2 dose based on efficacy and safety data. Treatment-related adverse events occurred in 98% of patients, with Grade ≥3 events in 63%. The drug is currently being evaluated in multiple Phase 2 and 3 trials, including waveLINE-010, waveLINE-007, and waveLINE-011, for various DLBCL treatment settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
FAQ
What is the current stock price of Merck & (MRK)?
The current stock price of Merck & (MRK) is $119.05 as of June 12, 2026.
What is the market cap of Merck & (MRK)?
The market cap of Merck & (MRK) is approximately 298.3B.